CEL SCI CORP
About CEL SCI CORP
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2014
- $264.0K
- Net income
- -$25.4M
- Total assets
- $28.2M
- Market cap
- $19.9M
- Operating margin
- 3823.1%
- Net margin
- -3915.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- -$648.9K
- Operating expenses
- $24.8M
- Operating income
- -$24.8M
- Net income
- $25.4M
- EPS (diluted)
- $-6.27
Balance sheet
- Total assets
- $28.2M
- Current assets
- $11.6M
- Total liabilities
- $12.2M
- Current liabilities
- $5.1M
- Shareholders’ equity
- $16.0M
Cash flow
- Operating cash flow
- -$17.1M
- Investing cash flow
- -$38.1K
- Financing cash flow
- $23.4M
- Net cash flow
- $6.2M
Statements via Polygon.io (SEC filings)
- Market cap
- $19.9M
- EPS (diluted)
- $-6.27
- Shares outstanding
- 14.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 8, 1983
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $25.4M in FY2014.
- Revenue grew 44% from FY2021 to FY2025.
- Trading 89% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review CEL SCI CORP.
Write a review
News about CEL SCI CORP
News & sentiment via Polygon.io
